Your browser doesn't support javascript.
loading
PP2A inhibition causes synthetic lethality in BRCA2-mutated prostate cancer models via spindle assembly checkpoint reactivation.
Wang, Jian; Chen, Yuke; Li, Shiwei; Liu, Wanchang; Zhou, Xiao Albert; Luo, Yefei; Xu, Zhanzhan; Xiong, Yundong; Cheng, Kaiqi; Ruan, Mingjian; Yu, Wei; Li, Xiaoman; Wang, Weibin; Wang, Jiadong.
Afiliação
  • Wang J; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Chen Y; Department of Urology, Peking University First Hospital, Beijing, China.
  • Li S; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Liu W; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Zhou XA; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Luo Y; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Xu Z; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Xiong Y; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Cheng K; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Ruan M; Department of Urology, Peking University First Hospital, Beijing, China.
  • Yu W; Department of Urology, Peking University First Hospital, Beijing, China.
  • Li X; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Wang W; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  • Wang J; Department of Radiation Medicine, School of Basic Medical Sciences, Peking University International Cancer Institute, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
J Clin Invest ; 134(1)2024 Jan 02.
Article em En | MEDLINE | ID: mdl-37934606

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Mutações Sintéticas Letais Limite: Animals / Humans / Male Idioma: En Revista: J Clin Invest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Mutações Sintéticas Letais Limite: Animals / Humans / Male Idioma: En Revista: J Clin Invest Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos